Please Wait.....
Report
Europe Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 244 Pages I Data Bridge Market Research
Europe breast cancer diagnostics market is projected to register a CAGR of 8.7% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030
Market Segmentation:
Europe Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Ireland, Rest of Europe) Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the Europe breast cancer diagnostics market are:
- Increasing breast cancer patients among the women population as well as men
- Rise in technological advancement for breast cancer diagnostic
Market Players
The key market players operating in the Europe breast cancer diagnostics market are:
- F-Hoffmann La Roche Ltd.
- Siemens Healthcare GmbH
- NanoString.
- Cepheid
- BIOMERIEUX
- Exact Sciences Corporation
- Biocept, Inc.
- Abacus ALS
TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50
2 MARKET SEGMENTATION 54
2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 69
4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71
5 EPIDEMIOLOGY 72
6 INDUSTRIAL INSIGHTS 73
7 REGULATORY FRAMEWORK 74
8 MARKET OVERVIEW 76
8.1 DRIVERS 78
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83
9 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84
9.1 OVERVIEW 85
9.2 IMAGING 88
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
9.2.1.2 ANALOG MAMMOGRAPHY 90
9.2.1.3 3D BREAST TOMOSYNTHESIS 90
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
9.2.1.7 OTHERS 90
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
9.2.2.1 OPTICAL IMAGING 91
9.2.2.2 BREAST ULTRASOUND 91
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
9.2.2.5 BREAST THERMOGRAPHY 92
9.2.3 BIOPSY 92
9.2.3.1 SURGICAL BIOPSY 93
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
9.2.3.3 CORE NEEDLE BIOPSY 93
9.2.3.4 IMAGE-GUIDED BIOPSY 93
9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
9.2.4 GENOMIC TEST 94
9.2.4.1 MOLECULAR TESTING 95
9.2.4.1.1 PD-L1 96
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
9.2.4.1.3 NTRK GENE FUSIONS 96
9.2.4.1.4 PI3KCA GENE MUTATION 96
9.2.4.2 MAMMAPRINT 96
9.2.4.3 ONCOTYPE DX 96
9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98
10 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99
10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105
11 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106
11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112
12 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114
12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119
13 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120
13.1 EUROPE 121
13.1.1 GERMANY 130
13.1.2 FRANCE 136
13.1.3 RUSSIA 142
13.1.4 ITALY 148
13.1.5 U.K. 154
13.1.6 SPAIN 160
13.1.7 TURKEY 166
13.1.8 NETHERLANDS 172
13.1.9 BELGIUM 178
13.1.10 SWITZERLAND 184
13.1.11 IRELAND 190
13.1.12 REST OF EUROPE 196
14 EUROPE BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 197
14.1 COMPANY SHARE ANALYSIS: EUROPE 197
15 SWOT ANALYSIS 198
16 COMPANY PROFILE 199
16.1 HOLOGIC, INC. 199
16.1.1 COMPANY SNAPSHOT 199
16.1.2 REVENUE ANALYSIS 199
16.1.3 COMPANY SHARE ANALYSIS 200
16.1.4 PRODUCT PORTFOLIO 200
16.1.5 RECENT DEVELOPMENTS 201
16.2 SIEMENS HEALTHCARE GMBH 202
16.2.1 COMPANY SNAPSHOT 202
16.2.2 REVENUE ANALYSIS 203
16.2.3 COMPANY SHARE ANALYSIS 203
16.2.4 PRODUCT PORTFOLIO 204
16.2.5 RECENT DEVELOPMENTS 204
16.3 F. HOFFMANN- LA ROCHE LTD 205
16.3.1 COMPANY SNAPSHOT 205
16.3.2 REVENUE ANALYSIS 205
16.3.3 COMPANY SHARE ANALYSIS 206
16.3.4 PRODUCT PORTFOLIO 206
16.3.5 RECENT DEVELOPMENTS 207
16.4 KONINKLIJKE PHILIPS N.V. 208
16.4.1 COMPANY SNAPSHOT 208
16.4.2 REVENUE ANALYSIS 208
16.4.3 COMPANY SHARE ANALYSIS 209
16.4.4 PRODUCT PORTFOLIO 209
16.4.5 RECENT DEVELOPMENTS 210
16.5 ABBOTT 211
16.5.1 COMPANY SNAPSHOT 211
16.5.2 REVENUE ANALYSIS 211
16.5.3 COMPANY SHARE ANALYSIS 212
16.5.4 PRODUCT PORTFOLIO 212
16.5.5 RECENT DEVELOPMENTS 212
16.6 ABACUS ALS 213
16.6.1 COMPANY SNAPSHOT 213
16.6.2 PRODUCT PORTFOLIO 213
16.6.3 RECENT DEVELOPMENTS 213
16.7 BD 214
16.7.1 COMPANY SNAPSHOT 214
16.7.2 REVENUE ANALYSIS 214
16.7.3 COMPANY SHARE ANALYSIS 215
16.7.4 PRODUCT PORTFOLIO 215
16.7.5 RECENT DEVELOPMENTS 215
16.8 BIOCEPT, INC. 216
16.8.1 COMPANY SNAPSHOT 216
16.8.2 REVENUE ANALYSIS 216
16.8.3 PRODUCT PORTFOLIO 217
16.8.4 RECENT DEVELOPMENTS 217
16.9 BIOMERIEUX 218
16.9.1 COMPANY SNAPSHOT 218
16.9.2 REVENUE ANALYSIS 218
16.9.3 PRODUCT PORTFOLIO 219
16.9.4 RECENT DEVELOPMENTS 219
16.10 BIO-RAD LABORATORIES, INC. 220
16.10.1 COMPANY SNAPSHOT 220
16.10.2 REVENUE ANALYSIS 220
16.10.3 PRODUCT PORTFOLIO 221
16.10.4 RECENT DEVELOPMENT 221
16.11 CEPHEID 222
16.11.1 COMPANY SNAPSHOT 222
16.11.2 REVENUE ANALYSIS 222
16.11.3 PRODUCT PORTFOLIO 223
16.11.4 RECENT DEVELOPMENT 223
16.12 EXACT SCIENCES CORPORATION 224
16.12.1 COMPANY SNAPSHOT 224
16.12.2 REVENUE ANALYSIS 224
16.12.3 COMPANY SHARE ANALYSIS 225
16.12.4 PRODUCT PORTFOLIO 225
16.12.5 RECENT DEVELOPMENTS 226
16.13 FUJIFILM CORPORATION 227
16.13.1 COMPANY SNAPSHOT 227
16.13.2 REVENUE ANALYSIS 227
16.13.3 PRODUCT PORTFOLIO 228
16.13.4 RECENT DEVELOPMENT 228
16.14 GENERAL ELECTRIC 229
16.14.1 COMPANY SNAPSHOT 229
16.14.2 REVENUE ANALYSIS 229
16.14.3 PRODUCT PORTFOLIO 230
16.14.4 RECENT DEVELOPMENTS 230
16.15 ILLUMINA, INC. 231
16.15.1 COMPANY SNAPSHOT 231
16.15.2 REVENUE ANALYSIS 231
16.15.3 PRODUCT PORTFOLIO 232
16.15.4 RECENT DEVELOPMENTS 232
16.16 MYRIAD GENETICS, INC. 233
16.16.1 COMPANY SNAPSHOT 233
16.16.2 REVENUE ANALYSIS 233
16.16.3 PRODUCT PORTFOLIO 234
16.16.4 RECENT DEVELOPMENT 234
16.17 NANOSTRING. 235
16.17.1 COMPANY SNAPSHOT 235
16.17.2 REVENUE ANALYSIS 235
16.17.3 PRODUCT PORTFOLIO 236
16.17.4 RECENT DEVELOPMENT 236
16.17.5 RECENT DEVELOPMENT 236
16.18 ONCOSTEM. 237
16.18.1 COMPANY SNAPSHOT 237
16.18.2 PRODUCT PORTFOLIO 237
16.18.3 RECENT DEVELOPMENT 237
16.19 PROVISTA DIAGNOSTICS. 238
16.19.1 COMPANY SNAPSHOT 238
16.19.2 PRODUCT PORTFOLIO 238
16.19.3 RECENT DEVELOPMENT 238
16.20 THERMO FISHER SCIENTIFIC INC. 239
16.20.1 COMPANY SNAPSHOT 239
16.20.2 REVENUE ANALYSIS 239
16.20.3 PRODUCT PORTFOLIO 240
16.20.4 RECENT DEVELOPMENT 240
17 QUESTIONNAIRE 241
18 RELATED REPORTS 244
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security